Tab Application Banner
  • Users Online: 624
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

Ahead of print publication  

We are in charge of treating myositis!

 Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana, Turkey

Correspondence Address:
Ilke Coskun Benlidayi,
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_54_20

How to cite this URL:
Benlidayi IC. We are in charge of treating myositis!. Indian J Rheumatol [Epub ahead of print] [cited 2020 Oct 27]. Available from:

Inflammatory myopathy/myositis is an umbrella term that encompasses polymyositis, dermatomyositis, sporadic inclusion-body myositis, immune-mediated necrotizing myopathy, and overlap myositis.[1] The prominent clinical feature is subacute to chronic onset of proximal muscle weakness. Patients may also present with extramuscular symptoms indicating the systemic inflammatory feature of the disease.[2],[3] Multiorgan involvement may include the skin, gastrointestinal system, joints, lungs, and heart.[3] Muscle enzymes, myositis-specific antibodies, electroneuromyography, skeletal muscle imaging, and muscle biopsy are used for diagnosis.[2]

Management of idiopathic inflammatory myositis should involve both pharmacological and nonpharmacological strategies. Pharmacological options vary including corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, cyclophosphamide, cyclosporine, tacrolimus, rituximab, and some other biological disease-modifying anti-rheumatic drugs. On the other hand, nonpharmacological options such as physical, occupational, and speech therapy should be directed meticulously according to patients' needs.[2]

In this regard, a multidisciplinary approach is desired for the management of inflammatory myositis. Hence, we are all in charge of treating myositis [Figure 1]. Let's “collect the inflammatory cells,” “patch the vacuoles,” and “remove the aggregates”!
Figure 1: Cartoon

Click here to view

  References Top

Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018;17:816-28.  Back to cited text no. 1
Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: Clinical approach and management. Front Neurol 2016;7:64.  Back to cited text no. 2
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol 2018;14:269-78.  Back to cited text no. 3


  [Figure 1]


     Search Pubmed for
    -  Benlidayi IC
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Article Figures

 Article Access Statistics
    PDF Downloaded34    

Recommend this journal